| Zacks Company Profile for Travere Therapeutics, Inc. (TVTX : NSDQ) |
|
|
| |
| • Company Description |
| Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.
Number of Employees: 497 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $57.36 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,460,400 shares |
| Shares Outstanding: 92.99 (millions) |
| Market Capitalization: $5,334.08 (millions) |
| Beta: 1.10 |
| 52 Week High: $60.10 |
| 52 Week Low: $15.03 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-2.83% |
-3.54% |
| 12 Week |
36.18% |
32.45% |
| Year To Date |
50.12% |
37.07% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
3611 VALLEY CENTRE DR SUITE 300
-
SAN DIEGO,CA 92130
USA |
ph: 888-969-7879
fax: 302-645-1280 |
ir@travere.com |
http://www.travere.com |
|
|
| |
| • General Corporate Information |
Officers
Eric Dube - Chief Executive Officer
Gary Lyons - Chairman
Christopher Cline - Chief Financial Officer
Sandra Calvin - Senior Vice President and Chief Accounting Officer
Roy D. Baynes - Director
|
|
Peer Information
Travere Therapeutics, Inc. (CORR.)
Travere Therapeutics, Inc. (RSPI)
Travere Therapeutics, Inc. (CGXP)
Travere Therapeutics, Inc. (BGEN)
Travere Therapeutics, Inc. (GTBP)
Travere Therapeutics, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 89422G107
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/05/26
|
|
Share - Related Items
Shares Outstanding: 92.99
Most Recent Split Date: (:1)
Beta: 1.10
Market Capitalization: $5,334.08 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.07 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.31 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 6.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/05/26 |
|
|
|
| |
